Q BioMed
Inc. (OTCQB:QBIO) To Present at the SeeThruEquity & The Brewer Group 2nd
Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22,
2016
New
York, NY – (February 16, 2016) – Q BioMed Inc. (OTCQB: QBIO) a
biotechnology acceleration company, today announced that the company will
present at the SeeThruEquity & The Brewer Group 2nd Annual
Innovations Investor Conference at The Ritz-Carlton in Miami on South Beach on
February 22, 2016.
Each
company will be provided with a 30-minute time slot to present to an audience
of investors and industry professionals and company management will also be
available for one-on-one meetings with institutional investors.
Conference
registration: complimentary for qualified
investors and equity research analysts.
To
stay informed on Q BioMed developments please visit our website www.qbiomed.com and
sign up for our news distribution.
Read this release
in full at http://www.investorideas.com/CO/QBIO/news/2016/02162.asp
About SeeThruEquity
Since
the company's founding in 2011, SeeThruEquity (STE) has been committed to its
core mission: providing impactful, high quality research on uncovered and
undercovered microcap stocks and hosting investor conferences throughout the
year. STE has been able to grow its research universe to over 176 names.
STE
conferences are the ultimate event for publicly traded companies with less than
$1 billion in market capitalization because it augments the conference
experience with the firm’s research which is part of Wall Street consensus and
available across industry leading platforms including Thomson First Call,
FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select
few. STE has hosted 20 investor
conferences which have showcased over 350 companies, attracted over 4500
attendees and have included over 1,700 1-on-1 meetings.
About The Brewer
Group
The
Brewer Group, Inc. (TBG) is an industry agnostic investment and consulting
company with assets ranging numerous sectors. TBG’s relationships with key
international decision makers spanning government development agencies,
financial institutions, multinational corporations, NGOs and numerous leaders
in sports and entertainment place TBG in a unique position to grow its
portfolio. TBG takes pride in identifying companies whose goal is to make a
social impact on the communities in which they serve. For further information,
please visit www.thebrewergroup.com.
About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development
company. We are focused on acquiring companies and biomedical assets. Q is
dedicated to providing these target companies and assets, strategic resources,
developmental support, and expansion capital to ensure they meet their
developmental potential enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements include, but are not limited
to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts.
Forward-looking statements are based on management’s current expectations and
are subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price. Factors that
could cause actual results to differ materially from those currently anticipated
are: risks related to our growth strategy; risks relating to the results of
research and development activities; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships; uncertainties
relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate, and retain key personnel; the
early stage of products under development; our need for substantial additional
funds; government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or circumstances on
which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
This news
is published on the Investorideas.com Newswire - a global digital news source
for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info:
http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication
and social media effective February 5th for three months: two thousand five
hundred per month.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
No comments:
Post a Comment